Urtoxazumab
Urtoxazumab is a humanized monoclonal antibody against diarrhoea caused by Escherichia coli, serotype O121. The drug is designed to bind to a toxin of this bacterium, so that it can be more easily broken down and eliminated from the body.[1][2]
References
- ↑ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
- ↑ López, EL; Contrini, MM; Glatstein, E; González Ayala, S; Santoro, R; Allende, D; Ezcurra, G; Teplitz, E; et al. (2009). "Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody Against Shiga-Like Toxin 2 in Healthy Adults and Pediatric STEC- Infected Patients". Antimicrobial Agents and Chemotherapy 54 (1): 239–243. doi:10.1128/AAC.00343-09. PMC 2798559. PMID 19822704.
|
---|
| Fungal ("-fung-") | |
---|
| Viral ("-v(i)[r]-") | |
---|
| Bacterial ("-ba(c)-") | Human ("-bacu-") | |
---|
| Mouse ("-baco-") | |
---|
| | |
---|
| Humanized ("-bazu-") | |
---|
|
---|
| Toxin ("-tox(a)-") | Human ("-toxu-") | |
---|
| Chimeric ("-toxaxi-") | |
---|
| Humanized ("-toxazu-") | |
---|
|
---|
| |
|